Zoetis Inc. (NYSE:ZTS) Shares Sold by Aaron Wealth Advisors LLC

by · The Markets Daily

Aaron Wealth Advisors LLC reduced its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 10.5% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 3,264 shares of the company’s stock after selling 383 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in Zoetis were worth $537,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Rakuten Securities Inc. boosted its position in Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 166 shares during the period. Navigoe LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at $30,000. Murphy & Mullick Capital Management Corp acquired a new stake in shares of Zoetis in the 4th quarter valued at $44,000. Sound Income Strategies LLC raised its stake in Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company’s stock worth $46,000 after acquiring an additional 164 shares in the last quarter. Finally, Bfsg LLC raised its stake in Zoetis by 614.6% during the 1st quarter. Bfsg LLC now owns 293 shares of the company’s stock worth $48,000 after acquiring an additional 252 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Activity

In related news, EVP Roxanne Lagano sold 652 shares of the firm’s stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the transaction, the executive vice president owned 15,129 shares of the company’s stock, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.18% of the stock is owned by company insiders.

Analysts Set New Price Targets

ZTS has been the topic of a number of recent research reports. UBS Group dropped their price objective on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and lowered their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Piper Sandler boosted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a report on Monday, May 12th. Finally, Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $212.13.

Read Our Latest Analysis on ZTS

Zoetis Stock Down 0.1%

ZTS stock opened at $159.09 on Thursday. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The firm’s 50-day simple moving average is $160.92 and its 200 day simple moving average is $162.32. The stock has a market cap of $70.83 billion, a PE ratio of 28.56, a price-to-earnings-growth ratio of 2.64 and a beta of 0.91.

Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The business’s revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.38 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.26%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis’s dividend payout ratio (DPR) is 35.91%.

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).